GSK plc
GLAXFOTCHealthcare● Active
$23.54
$-0.40(-1.67%)
Market Cap$94.4B
P/E Ratio—
52W High$31.48
52W Low$17.15
GSK plc (GLAXF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GLAXF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
$0.61
Est. $0.57 · +7.9%
Revenue
$10.09B
Est. $10.09B · -0.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
GLAXF reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $3.50B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$3.50B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 28, 2026 | $0.62 | — | — | — | $11.05B | — |
| ▲ Q2 FY2026 | Apr 29, 2026 | $0.57 | $0.61 | +7.9% | $10.09B | $10.09B | -0.1% |
| ▲ Q1 FY2026 | Feb 4, 2026 | $0.32 | $0.34 | +7.1% | $11.61B | $11.40B | +1.9% |
| ▼ Q4 FY2025 | Oct 29, 2025 | $0.63 | $0.49 | -22.2% | $8.55B | $11.12B | -23.1% |
| ▼ Q3 FY2025 | Jul 30, 2025 | $0.59 | $0.48 | -19.6% | $10.88B | $10.85B | +0.3% |
| ▲ Q2 FY2025 | Apr 29, 2025 | $54.81 | $59.65 | +8.8% | $9.70B | $10.56B | -8.1% |
| ▲ Q1 FY2025 | Feb 5, 2025 | $0.31 | $28.74 | +9171.0% | $10.16B | $12.20B | -16.8% |
| ▲ Q4 FY2024 | Oct 30, 2024 | $43.20 | $49.70 | +15.1% | $10.50B | $12.92B | -18.7% |
Q3 FY2026
Jul 28, 2026
EPS Actual
—
EPS Est.
$0.62
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Beat
EPS Actual
$0.61
EPS Est.
$0.57
EPS Surpr.
+7.9%
Revenue
$10.09B
Q1 FY2026
Feb 4, 2026Beat
EPS Actual
$0.34
EPS Est.
$0.32
EPS Surpr.
+7.1%
Revenue
$11.61B
Q4 FY2025
Oct 29, 2025Miss
EPS Actual
$0.49
EPS Est.
$0.63
EPS Surpr.
-22.2%
Revenue
$8.55B
Q3 FY2025
Jul 30, 2025Miss
EPS Actual
$0.48
EPS Est.
$0.59
EPS Surpr.
-19.6%
Revenue
$10.88B
Q2 FY2025
Apr 29, 2025Beat
EPS Actual
$59.65
EPS Est.
$54.81
EPS Surpr.
+8.8%
Revenue
$9.70B
Q1 FY2025
Feb 5, 2025Beat
EPS Actual
$28.74
EPS Est.
$0.31
EPS Surpr.
+9171.0%
Revenue
$10.16B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
$49.70
EPS Est.
$43.20
EPS Surpr.
+15.1%
Revenue
$10.50B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.39 | $0.40 | $0.41 | 1 |
| Q3 FY2027 | $0.78 | $0.80 | $0.83 | 1 |
| Q2 FY2027 | $0.65 | $0.66 | $0.68 | 1 |
| Q1 FY2027 | $0.65 | $0.67 | $0.69 | 1 |
| Q4 FY2026 | $0.39 | $0.40 | $0.41 | 1 |
| Q3 FY2026 | $0.71 | $0.72 | $0.74 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $12.1B | $12.3B | $12.6B | 3 |
| Q3 FY2027 | $12.1B | $12.3B | $12.6B | 3 |
| Q2 FY2027 | $11.2B | $11.4B | $11.7B | 3 |
| Q1 FY2027 | $10.5B | $10.6B | $10.9B | 4 |
| Q4 FY2026 | $11.8B | $12.0B | $12.3B | 4 |
| Q3 FY2026 | $11.6B | $11.9B | $12.3B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +7.9% | $27.31 | $27.08 | -0.84% |
| ▲ Q1 FY2026 | Feb 4, 2026 | +7.1% | $26.02 | $27.63 | +6.19% |
| ▼ Q4 FY2025 | Oct 29, 2025 | -22.2% | $20.97 | $21.74 | +3.67% |
| ▼ Q3 FY2025 | Jul 30, 2025 | -19.6% | $18.76 | $18.76 | +0.00% |
| ▲ Q2 FY2025 | Apr 29, 2025 | +8.8% | $18.45 | $18.81 | +1.95% |
| ▲ Q1 FY2025 | Feb 5, 2025 | +9171.0% | $17.33 | $18.38 | +6.06% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +15.1% | $18.77 | $18.32 | -2.40% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +12.8% | $19.50 | $19.29 | -1.08% |
Q2 FY2026-0.84%
Report Date
Apr 29, 2026
EPS Beat/Miss
+7.9%
Price Before
$27.31
Price After
$27.08
Q1 FY2026+6.19%
Report Date
Feb 4, 2026
EPS Beat/Miss
+7.1%
Price Before
$26.02
Price After
$27.63
Q4 FY2025+3.67%
Report Date
Oct 29, 2025
EPS Beat/Miss
-22.2%
Price Before
$20.97
Price After
$21.74
Q3 FY2025+0.00%
Report Date
Jul 30, 2025
EPS Beat/Miss
-19.6%
Price Before
$18.76
Price After
$18.76
Q2 FY2025+1.95%
Report Date
Apr 29, 2025
EPS Beat/Miss
+8.8%
Price Before
$18.45
Price After
$18.81
Q1 FY2025+6.06%
Report Date
Feb 5, 2025
EPS Beat/Miss
+9171.0%
Price Before
$17.33
Price After
$18.38
Q4 FY2024-2.40%
Report Date
Oct 30, 2024
EPS Beat/Miss
+15.1%
Price Before
$18.77
Price After
$18.32
Q3 FY2024-1.08%
Report Date
Jul 31, 2024
EPS Beat/Miss
+12.8%
Price Before
$19.50
Price After
$19.29
Avg Beat Reaction+1.65%
Avg Miss Reaction+1.83%
Beat Rate6 / 8 quarters
Largest Move+6.19% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GLAXF ends December
GSK plc (GLAXF) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $0.61 — beating the analyst consensus of $0.57 by +7.9%. GLAXF has beaten EPS estimates for 2 consecutive quarters. The next GLAXF earnings date is expected around September 1, 2026.
Each quarter, investors track GLAXF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GLAXF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GLAXF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GLAXF earnings · 5 questionsGSK plc's next earnings report is expected around September 1, 2026. GLAXF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GLAXF historically reports after market close (AMC).
GLAXF earnings datewhen is GLAXF earningsGLAXF next earnings datewhen does GLAXF report earningsGLAXF earnings calendar
▸ Source: FMP · GSK plc SEC filings · US GAAP · GSK plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026